Dr William Borj Tabayoyong, MD,PHD - Medicare Urology in Rochester, NY

Dr William Borj Tabayoyong, MD,PHD is a medicare enrolled "Urology" physician in Rochester, New York. He graduated from medical school in 2011 and has 13 years of diverse experience with area of expertise as Urology. He is a member of the group practice University Urology Associates and his current practice location is 601 Elmwood Ave, Rochester, New York. You can reach out to his office (for appointments etc.) via phone at (585) 275-2838.

Dr William Borj Tabayoyong is licensed to practice in New York (license number 299919) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1124319850.

Contact Information

Dr William Borj Tabayoyong, MD,PHD
601 Elmwood Ave,
Rochester, NY 14642-0001
(585) 275-2838
(585) 273-1068



Physician's Profile

Full NameDr William Borj Tabayoyong
GenderMale
SpecialityUrology
Experience13 Years
Location601 Elmwood Ave, Rochester, New York
Accepts Medicare AssignmentsYes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.
  Medical Education and Training:
  • Dr William Borj Tabayoyong graduated from medical school in 2011
  NPI Data:
  • NPI Number: 1124319850
  • Provider Enumeration Date: 04/28/2011
  • Last Update Date: 07/03/2023
  Medicare PECOS Information:
  • PECOS PAC ID: 4486980513
  • Enrollment ID: I20190729000497

Medical Identifiers

Medical identifiers for Dr William Borj Tabayoyong such as npi, medicare ID, medicare PIN, medicaid, etc.
IdentifierTypeStateIssuer
1124319850NPI-NPPES

Medical Taxonomies and Licenses

TaxonomyTypeLicense (State)Status
208800000XUrology 299919 (New York)Primary

Medical Facilities Affiliation

Facility NameLocationFacility Type
Strong Memorial HospitalRochester, NYHospital

Group Practice Association

Group Practice NameGroup PECOS PAC IDNo. of Members
University Urology Associates488064253757

News Archive

Cost effectiveness study looks at potential value of new genetic test for guiding chemotherapy treatment

For the 29,000 patients in the United States with metastatic colorectal cancer, chemotherapy with irinotecan is a standard treatment that has been shown to improve survival. But for more than one in 10 of these patients, a variation in their DNA means that this treatment could result in a severe reduction in their white blood cell count, leading to a high risk of bacterial infection and possible subsequent death.

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

Pantera Lux Paclitaxel Releasing Balloon highly promising for DES restenosis

Six-month results from the DELUX registry demonstrating excellent safety and efficacy results for the Pantera Lux Paclitaxel Releasing Balloon in more than 1000 patients were presented by Ralph Toelg, MD, Segeberger Heart Center Clinic, Germany, and Thomas Schmitz, MD, Elisabeth Hospital, Germany, at the EuroPCR 2012 congress in Paris last week.

ERC offers grants to early career researchers to conduct pioneering research projects

Why is the world so green? What can we eat to prevent dementia? Are our eyes really the windows to our personalities? 403 talented early career researchers have been awarded European Research Council grants to answer such questions.

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

Read more Medical News

› Verified 2 days ago

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr William Borj Tabayoyong allows following entities to bill medicare on his behalf.
Entity NameUniversity Urology Associates
Entity TypePart B Supplier - Clinic/group Practice
Entity IdentifiersNPI Number: 1952357493
PECOS PAC ID: 4880642537
Enrollment ID: O20050110000246

News Archive

Cost effectiveness study looks at potential value of new genetic test for guiding chemotherapy treatment

For the 29,000 patients in the United States with metastatic colorectal cancer, chemotherapy with irinotecan is a standard treatment that has been shown to improve survival. But for more than one in 10 of these patients, a variation in their DNA means that this treatment could result in a severe reduction in their white blood cell count, leading to a high risk of bacterial infection and possible subsequent death.

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

Pantera Lux Paclitaxel Releasing Balloon highly promising for DES restenosis

Six-month results from the DELUX registry demonstrating excellent safety and efficacy results for the Pantera Lux Paclitaxel Releasing Balloon in more than 1000 patients were presented by Ralph Toelg, MD, Segeberger Heart Center Clinic, Germany, and Thomas Schmitz, MD, Elisabeth Hospital, Germany, at the EuroPCR 2012 congress in Paris last week.

ERC offers grants to early career researchers to conduct pioneering research projects

Why is the world so green? What can we eat to prevent dementia? Are our eyes really the windows to our personalities? 403 talented early career researchers have been awarded European Research Council grants to answer such questions.

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

Read more Medical News

› Verified 2 days ago

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr William Borj Tabayoyong is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing AddressPractice Location Address
Dr William Borj Tabayoyong, MD,PHD
601 Elmwood Ave Box 656,
Rochester, NY 14642-0001

Ph: (585) 275-2838
Dr William Borj Tabayoyong, MD,PHD
601 Elmwood Ave,
Rochester, NY 14642-0001

Ph: (585) 275-2838

News Archive

Cost effectiveness study looks at potential value of new genetic test for guiding chemotherapy treatment

For the 29,000 patients in the United States with metastatic colorectal cancer, chemotherapy with irinotecan is a standard treatment that has been shown to improve survival. But for more than one in 10 of these patients, a variation in their DNA means that this treatment could result in a severe reduction in their white blood cell count, leading to a high risk of bacterial infection and possible subsequent death.

AMRI announces acquisition of Hyaluron

AMRI today announced the acquisition of Hyaluron Inc., expanding AMRI's contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

Pantera Lux Paclitaxel Releasing Balloon highly promising for DES restenosis

Six-month results from the DELUX registry demonstrating excellent safety and efficacy results for the Pantera Lux Paclitaxel Releasing Balloon in more than 1000 patients were presented by Ralph Toelg, MD, Segeberger Heart Center Clinic, Germany, and Thomas Schmitz, MD, Elisabeth Hospital, Germany, at the EuroPCR 2012 congress in Paris last week.

ERC offers grants to early career researchers to conduct pioneering research projects

Why is the world so green? What can we eat to prevent dementia? Are our eyes really the windows to our personalities? 403 talented early career researchers have been awarded European Research Council grants to answer such questions.

Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.

Read more News

› Verified 2 days ago


Urology Doctors in Rochester, NY

Jimena Cubillos, MD
Urology
Medicare: Medicare Enrolled
Practice Location: 601 Elmwood Ave, Box 656, Rochester, NY 14642
Phone: 585-275-3342    Fax: 585-273-1070
Erdal S Erturk, MD
Urology
Medicare: Not Enrolled in Medicare
Practice Location: 601 Elmwood Ave, Rochester, NY 14642
Phone: 585-275-3690    Fax: 585-273-1068
Fernando Caumont, MD
Urology
Medicare: Accepting Medicare Assignments
Practice Location: 2615 Culver Rd Ste 100, Rochester, NY 14609
Phone: 585-336-5320    Fax: 585-336-9114
Mr. John R Valvo, MD
Urology
Medicare: Accepting Medicare Assignments
Practice Location: 2615 Culver Rd, Suite 100, Rochester, NY 14609
Phone: 585-336-5320    Fax: 585-336-9114
Robert S. Davis, M.D.
Urology
Medicare: Not Enrolled in Medicare
Practice Location: 601 Elmwood Ave, Rochester, NY 14642
Phone: 585-275-5282    Fax: 585-273-1068
Hani Rashid, M.D.
Urology
Medicare: Accepting Medicare Assignments
Practice Location: 400 White Spruce Blvd, Suite B, Rochester, NY 14623
Phone: 585-424-6490    Fax: 585-424-1689
Dr. Anees Ahmed Fazili, M.D.
Urology
Medicare: Accepting Medicare Assignments
Practice Location: 2615 Culver Rd, Rochester, NY 14609
Phone: 585-336-5320    Fax: 585-336-9114

Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.